<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Venous thromboembolism: Initiation of anticoagulation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Venous thromboembolism: Initiation of anticoagulation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Venous thromboembolism: Initiation of anticoagulation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregory YH Lip, MD, FRCPE, FESC, FACC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Russell D Hull, MBBS, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jess Mandel, MD, MACP, ATSF, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James D Douketis, MD, FRCPC, FACP, FCCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 03, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H8155788">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Venous thromboembolism (VTE) is comprised of two entities, deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE has significant morbidity and mortality for both the inpatient and outpatient population. The risk of recurrent thrombosis and embolization is highest in the first few days and weeks following diagnosis. Thus, initial anticoagulation during the first few days (ie, 0 to 10 days) is critical in the prevention of recurrence and VTE-related death.
        </p>
        <p>
         The agents used, timing, duration, and dosing of initial anticoagulation for the treatment of VTE are discussed in this topic. The indications and overview of VTE treatment, as well as long-term (3 to 12 months) and extended (indefinite) anticoagulation for patients with VTE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at high risk of bleeding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
         The approach to anticoagulation outlined in this topic is, in general, consistent with strategies outlined by several international societies including the American College of Chest Physicians, the American College of Physicians, the European Society of Cardiology, the European Respiratory Society, and others [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8155794">
         <span class="h1">
          NOMENCLATURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the purposes of discussion in this topic, the following terms apply:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial anticoagulation refers to anticoagulant therapy that is administered immediately following diagnosis of acute VTE; it is often given over the first few days (typically from 0 to 10 days) while planning for long-term anticoagulation. Long-term anticoagulant therapy is typically administered for a finite period beyond the initial period, usually three to six months and occasionally up to 12 months. Extended anticoagulation usually refers to therapy that is administered indefinitely. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Factor Xa and direct thrombin inhibitors have a variety of names including newer/novel oral anticoagulants, non-vitamin K antagonist oral anticoagulants (NOAs, NOACs), direct oral anticoagulants (DOACs), and target-specific oral anticoagulants (TOACs, TSOACs) [
         <a href="#rid5">
          5
         </a>
         ]. Throughout this topic we refer to these agents by their pharmacologic class, factor Xa and direct thrombin inhibitors. (See
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15187019">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Details of the indications for anticoagulation, including those for patients with isolated distal DVT and subsegmental PE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Anticoagulant therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1055548080">
         <span class="h1">
          BLEEDING RISK
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients, the decision to anticoagulate should be individualized and the benefits of VTE prevention carefully weighed against the risk of bleeding  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef107543" href="/z/d/graphic/107543.html" rel="external">
          table 2
         </a>
         ). Risk factors for bleeding that influence whether to anticoagulate are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Assessing bleeding risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Assessing the risk of bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8155806">
         <span class="h1">
          SELECTION OF AGENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial anticoagulation refers to systemic anticoagulation administered immediately following the diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE; typically
         <strong>
          first 0 to 10 days
         </strong>
         ). It is often administered while a decision regarding long-term anticoagulation is being made. When the decision is made to administer anticoagulant therapy, it should be started immediately since a delay may potentially increase the risk of life-threatening embolization [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         Options for initial anticoagulation include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low molecular weight (LMW) heparin (see
         <a class="local">
          'Low molecular weight heparin'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          Fondaparinux
         </a>
         (see
         <a class="local">
          'Fondaparinux'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          Unfractionated heparin
         </a>
         (UFH) (see
         <a class="local">
          'Unfractionated heparin'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral factor Xa inhibitors or direct thrombin inhibitors (see
         <a class="local">
          'Direct factor Xa and thrombin inhibitors'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Our approach is generally consistent with that of other experts including the American College of Chest Physicians, and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fthrombosiscanada.ca%2Ftools%2F&amp;token=gEtwewdcY7C1ntnnSMiNkCkv9FuA5wq%2BxyEeze7yt6g9iLjVJlO3PWCMGBJ5vHD7&amp;TOPIC_ID=95336" target="_blank">
          Thrombosis Canada
         </a>
         [
         <a href="#rid4">
          4,8-10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2043558158">
         <span class="h2">
          General population
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the exception of patients who are pregnant, have active cancer, or have severely impaired renal function (eg, creatinine clearance [CrCl] &lt;30 mL/minute) we and others suggest the following approach  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid4">
          4,8
         </a>
         ]:
        </p>
        <p>
         For most patients with VTE who are hemodynamically stable, we suggest subcutaneous LMW heparin or
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         , or the oral factor Xa inhibitors,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         or
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         , rather than intravenous UFH. This preference is based upon limited data that suggest that LMW heparin and fondaparinux are superior to UFH, and data that also suggest that the DOACs have similar efficacy to LMW heparin/
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . However, in practice, a decision between these agents is usually made based upon clinician experience as well as the risks of bleeding, patient comorbidities, preferences, cost, and convenience  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 3
         </a>
         ). As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DOACs
         </strong>
         –
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          Rivaroxaban
         </a>
         and
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         are the only DOACs that have been studied and approved by regulatory agencies as
         <strong>
          mono
         </strong>
         therapy (ie, no pretreatment with heparin is necessary) for the treatment of patients with VTE. They may be preferred in those who wish to avoid the burden of injections in whom convenience or oral medication is a personal preference. Importantly, LMW heparin (or UFH) should be administered if there is a delay in obtaining these anticoagulants (eg, availability needs to be assured). (See
         <a class="local">
          'Direct factor Xa and thrombin inhibitors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When prescribing the direct thrombin inhibitor
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         , or the factor Xa inhibitor
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         , we suggest that a short course of heparin (typically LMW heparin) be administered for five days prior to transitioning to oral therapy (ie, sequential therapy also known as dual therapy, although the agents should not be administered together) since their efficacy as monotherapeutic agents has not been studied or approved. Importantly, these agents should not be administered simultaneously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Importantly, these DOAC agents are
         <strong>
          not
         </strong>
         suitable for the treatment of hemodynamically unstable PE or massive iliofemoral DVT (eg, phlegmasia cerulea dolens) where their efficacy has not been adequately studied and their use may interfere with potential therapy (eg, thrombolytic therapy). (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Phlegmasia cerulea dolens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Hemodynamically unstable patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LMW heparin
         </strong>
         – Subcutaneous LMW heparin may be preferred in those in whom oral anticoagulation is not feasible (eg, poor oral intake, malabsorption) or contraindicated (eg, pregnancy). (See
         <a class="local">
          'Low molecular weight heparin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          Fondaparinux
         </a>
         – Subcutaneous fondaparinux is an acceptable alternative to subcutaneous LMW heparin (eg, heparin-induced thrombocytopenia [HIT]). (See
         <a class="local">
          'Fondaparinux'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous (IV) UFH
         </strong>
         – IV UFH must be administered in the inpatient setting and is therefore not suitable as an outpatient therapy. IV UFH is our preferred agent for select populations of patients discussed below. (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         below and
         <a class="local">
          'Renal failure'
         </a>
         below and
         <a class="local">
          'Hemodynamic instability'
         </a>
         below and
         <a class="local">
          'Extensive clot burden'
         </a>
         below and
         <a class="local">
          'Anticipated need for discontinuation or reversal'
         </a>
         below and
         <a class="local">
          'Obesity or poor subcutaneous absorption'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subcutaneous UFH may be an alternative to IV UFH, administered in a weight-based fixed-dose regimen (333 IU/kg initial, then 250 IU/kg subcutaneous twice a day) without activated thromboplastin time monitoring.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         cannot be administered as the only initial anticoagulant for the treatment of patients with VTE. However, when chosen as the long-term anticoagulant it must be co-administered with heparin so that full anticoagulation is assured. (See
         <a class="local">
          'Transitioning to maintenance therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1911415678">
         <span class="h2">
          Special populations
         </span>
         <span class="headingEndMark">
          —
         </span>
         When choosing an initial anticoagulant, patients with malignancy, pregnant women, outpatients, and those with a history of heparin-induced thrombocytopenia (HIT) deserve special consideration  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1225023498">
         <span class="h3">
          Renal failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV UFH is our preferred anticoagulant in those with severe renal failure (eg, CrCl &lt;30 mL/minute) since renal adjustment is not required for therapeutic anticoagulation. (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1399166472">
         <span class="h3">
          Hemodynamic instability
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV UFH is our preferred anticoagulant in those who are hemodynamically unstable since thrombolysis, interventional procedure, or surgery may need to be considered in this population. (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1042474978">
         <span class="h3">
          Extensive clot burden
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV UFH is our preferred anticoagulant for those patients with extensive DVT or with phlegmasia cerulea dolens, or those with massive or submassive PE which is based upon an anticipated need for a procedural or surgical intervention. In addition, the DOACs and LMW heparin have not been adequately tested in this population. (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H58834905">
         <span class="h3">
          Anticipated need for discontinuation or reversal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since IV UFH has a short half-life (three to five hours) and a known reversibility agent (
         <a class="drug drug_general" data-topicid="9831" href="/z/d/drug information/9831.html" rel="external">
          protamine sulfate
         </a>
         ), it is our preferred anticoagulant for those patients in whom there is a high likelihood that anticoagulation will need to be discontinued or reversed (eg, patients at risk of bleeding or in need of a procedural or surgical intervention). (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1597360604">
         <span class="h3">
          Obesity or poor subcutaneous absorption
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no preferred agent in patients who are obese. However, therapeutic anticoagulation can be assured with IV UFH. IV UFH may also be an alternative to subcutaneous LMW heparin when subcutaneous absorption is potentially poor (eg, massive edema, anasarca).
        </p>
        <p class="headingAnchor" id="H1023440215">
         <span class="h3">
          Malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with active malignancy and acute VTE who have a reasonable life expectancy and adequate renal function (CrCl ≥30 mL/minute), low molecular weight (LMW) heparin or a DOAC is appropriate. Initial agents in this population are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">
          "Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4282273718">
         <span class="h3">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pregnant women with acute VTE, adjusted-dose subcutaneous LMW heparin is the preferred agent for initial anticoagulation because it has a more favorable safety profile, especially when compared with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/1350.html" rel="external">
          "Venous thromboembolism in pregnancy and postpartum: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">
          "Use of anticoagulants during pregnancy and postpartum"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H248857706">
         <span class="h3">
          Heparin-induced thrombocytopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute VTE may have a prior history of HIT or may develop HIT during parenteral therapy with heparin. For both populations, heparin is contraindicated (ie, UFH, LMW heparin, heparin flushes, heparin-bonded catheters, and heparin-containing medications) and non-heparin anticoagulants are preferred. The diagnosis and management of patients with HIT are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">
          "Clinical presentation and diagnosis of heparin-induced thrombocytopenia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3621011956">
         <span class="h1">
          OUTPATIENT ANTICOAGULATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Not all patients who have acute VTE need to be admitted to the hospital for initial anticoagulation. Several randomized trials and meta-analyses, most of which have compared outpatient therapy with subcutaneous low molecular weight heparin with inpatient therapy with intravenous
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         suggest that, in select populations, anticoagulation at home is safe and effective. Patient selection is critical when considering outpatient therapy for patients with deep vein thrombosis and/or pulmonary embolism, the details of which are discussed separately  (
         <a class="graphic graphic_table graphicRef70140" href="/z/d/graphic/70140.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Outpatient versus inpatient therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Outpatient anticoagulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8155812">
         <span class="h1">
          ANTICOAGULANT AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with VTE, the greatest risk of embolization is during the first few days following the diagnosis, particularly if patients are not anticoagulated. Thus, anticoagulant therapy should be started
         <strong>
          immediately
         </strong>
         as a delay may potentially increase the risk of life-threatening embolization. Baseline coagulation tests (prothrombin time, international normalized ratio [INR], activated partial thromboplastin time [aPTT]) should be drawn prior to the initiation of anticoagulation to guide therapy. The timing, duration, and dose of initial anticoagulation vary with the agent selected and are discussed in the sections below.
        </p>
        <p class="headingAnchor" id="H796357734">
         <span class="h2">
          Low molecular weight heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low molecular weight (LMW) heparin is our preferred anticoagulant for those with active cancer or pregnancy, for those in whom
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         , or
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         is chosen as the agent for long-term use, as well as for those in whom it is anticipated that therapeutic anticoagulation cannot be assured via the oral route (eg, malabsorption, vomiting). For those in whom
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         or
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         are chosen as the oral agent for long-term use, LMW heparin is not necessary unless these agents are unavailable or delayed. (See
         <a class="local">
          'Selection of agent'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13608216">
         <span class="h3">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial therapeutic dose of LMW heparin (eg,
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          dalteparin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">
          tinzaparin
         </a>
         ) varies by product. Dosing is typically weight-based and renally adjusted, and all are administered subcutaneously. Typical starting doses are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          Enoxaparin
         </a>
         1 mg/kg twice daily (preferred); alternatively, 1.5 mg/kg once daily can be used in selected non-obese inpatients; for home treatment, the twice daily regimen is better studied and therefore preferred by many experts [
         <a href="#rid11">
          11,12
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9319" href="/z/d/drug information/9319.html" rel="external">
          Dalteparin
         </a>
         200 units/kg once daily or 100 units/kg twice daily (eg, patients with absorption concerns)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">
          Tinzaparin
         </a>
         175 units/kg once daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10060" href="/z/d/drug information/10060.html" rel="external">
          Nadroparin
         </a>
         171 units/kg once daily or 86 units/kg twice daily (not available in the United States)
        </p>
        <p>
        </p>
        <p>
         Dosing for patients with renal insufficiency are listed in the tables  (
         <a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'LMW heparin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13608222">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence from several randomized trials and meta-analyses have reported that, compared with intravenous (IV) and subcutaneous
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH), subcutaneous LMW heparin has higher rates of thrombus regression and lower rates of recurrent thrombosis, major bleeding, and mortality [
         <a href="#rid8">
          8,13-27
         </a>
         ]. However, the data are fraught with methodologic flaws, including publication bias in favor of LMW heparin. None of the different formulations appear to be superior to the other [
         <a href="#rid28">
          28
         </a>
         ]. Data that support the use of LMW heparin include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2017 meta-analysis of 29 studies that compared LMW heparin with IV or subcutaneous UFH in patients with acute VTE (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]), at three months LMW heparin was associated with the following [
         <a href="#rid27">
          27
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fewer thrombotic complications (eg, recurrence, extension, embolization) (3.7 versus 5.1 percent; odds ratio [OR] 0.70, 95% CI 0.56-0.90)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Improved thrombus regression (51 versus 42 percent; OR 0.71, 95% CI 0.61-0.82)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduced rates of major hemorrhage (1.5 versus 2.1 percent; OR 0.69, 95% CI 0.5-0.95)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Non-significant reduction in mortality (4.8 versus 5.7 percent; OR 0.84, 95% CI 0.70-1.01)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An older meta-analysis of 13 studies of patients with acute VTE performed between 1980 and 1994 reported that, compared with UFH, LMW heparin was associated with a lower rate of both recurrent VTE (2.7 versus 7 percent) and major bleeding (0.9 versus 3.2 percent) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 1999 meta-analysis of 11 trials of patients with acute DVT found a lower mortality rate at three to six months among patients treated with LMW heparin, compared with those receiving UFH (OR 0.71, 95% CI 0.53-0.94) [
         <a href="#rid20">
          20
         </a>
         ]. Differences in recurrent thromboembolism and bleeding complications were not different between the two treatments.
        </p>
        <p>
        </p>
        <p>
         Once daily regimens of LMW heparin appear to be as effective as twice daily regimens. Meta-analyses of trials directly comparing once versus twice daily administration found no convincing differences in recurrent thrombosis, major hemorrhage, or mortality [
         <a href="#rid18">
          18,19,29-35
         </a>
         ]. One large randomized trial of 900 patients with symptomatic DVT, a third of whom also had PE, compared the LMW heparin
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         , administered as a standard twice daily regimen (1 mg/kg twice daily), with a lower once daily regimen (1.5 mg/kg per day) [
         <a href="#rid18">
          18
         </a>
         ]. Although rates of recurrence (3 versus 4 percent) and hemorrhage (1 versus 2 percent) were lower with the twice daily regimen, the difference was not significant and may have been explained by the lower total daily dose administered in the once daily treatment group. In another meta-analysis, once daily regimens were associated lower rates of major bleeding but at the expense of an increased rate of VTE recurrence [
         <a href="#rid35">
          35
         </a>
         ]. Except for enoxaparin, we prefer, when once daily dosing is being considered, that it be administered at the same total daily dose as a twice daily schedule.
        </p>
        <p>
         The LMW heparins have a number of advantages over
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         [
         <a href="#rid36">
          36,37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Advantages and limitations'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater bioavailability when given by subcutaneous injection
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Duration of the anticoagulant effect is longer, permitting once or twice daily administration
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fixed dosing is feasible because the anticoagulant response (anti-Xa activity) correlates well with body weight
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory monitoring is not necessary (correlation between anti-Xa activity and bleeding or recurrent thrombosis is poor)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower risk of heparin-induced thrombocytopenia (HIT)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use as an outpatient therapy
        </p>
        <p>
        </p>
        <p>
         Disadvantages of LMW heparin compared with UFH include the higher cost, and, although protamine is an antidote for hemorrhage, its effect is incomplete. In addition, efficacy is less certain in the obese population, in patients with renal failure, and in older patients who are underweight (&lt;45 kg). LMW heparin should be avoided or dose adjustments made in these circumstances  (
         <a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Other complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'LMW heparin standard dosing'
         </a>
         .)
        </p>
        <p>
         LMW heparin also appears to be as effective as once daily subcutaneous
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         . (See
         <a class="local">
          'Fondaparinux'
         </a>
         below.)
        </p>
        <p>
         Trials directly comparing LMW heparin with oral factor Xa and direct thrombin inhibitors as initial therapies for acute DVT have not been performed. (See
         <a class="local">
          'Direct factor Xa and thrombin inhibitors'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Direct thrombin and factor Xa inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13607339">
         <span class="h2">
          Fondaparinux
         </span>
         <span class="headingEndMark">
          —
         </span>
         As an alternative to LMW heparin,
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         is an acceptable anticoagulant for most nonpregnant patients with newly diagnosed VTE (eg, patients with HIT). (See
         <a class="local">
          'Selection of agent'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13610792">
         <span class="h3">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          Fondaparinux
         </a>
         is typically dosed according to patient weight as 5 mg once daily (&lt;50 kg), 7.5 mg once daily (50 to 100 kg), and 10 mg (&gt;100 kg). Fondaparinux is renally excreted. Further information on dosing and adverse effects are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">
          "Fondaparinux: Dosing and adverse effects", section on 'Pharmacology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13610798">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although subcutaneous
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         is less well studied than either LMW heparin or UFH in this setting, fondaparinux appears to have a similar efficacy and safety profile to LMW heparin [
         <a href="#rid38">
          38
         </a>
         ]. One multicenter trial of 2205 patients with acute DVT were randomized to receive fondaparinux, 7.5 mg subcutaneously once daily (5 mg in patients weighing &lt;50 kg; 10 mg &gt;100 kg), or
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         1 mg/kg subcutaneously twice daily with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , for at least five days. There was no difference in the rate of recurrent thromboembolism (4 percent), major bleeding (1 percent), or mortality rates (3 versus 4 percent) between the two treatments. A meta-analysis of pentasaccharides that included fondaparinux also reported similar efficacy when fondaparinux was given in combination with warfarin [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="local">
          'Selection of agent'
         </a>
         above.)
        </p>
        <p>
         Subcutaneous
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         and IV UFH also appear to have similar effects on mortality, recurrent thromboembolism, and major bleeding. This was demonstrated by a trial that randomly assigned 2213 patients with acute PE to receive either subcutaneous fondaparinux or IV UFH [
         <a href="#rid40">
          40
         </a>
         ]. The trial found no difference in mortality (5.2 versus 4.3 percent with IV UFH), recurrent thromboembolic events (3.8 versus 5 percent with IV UFH), or major bleeding (2 versus 2.3 percent with IV UFH).
        </p>
        <p>
         Dosing and adverse effects of
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">
          "Fondaparinux: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13607345">
         <span class="h2">
          Unfractionated heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) is our preferred anticoagulant for patients with severe renal failure (eg, CrCl &lt;30 mL/minute) and for patients in whom there is a high likelihood that acute reversal of anticoagulation will be needed (eg, procedure or at increased risk of bleeding) as well as those with hemodynamic instability especially if thrombolysis is being considered, and extensive clot burden (eg, phlegmasia cerulea dolens, submassive PE). It may also be an alternative to LMW heparin in patients suspected to have poor subcutaneous absorption (eg, edema or obesity). (See
         <a class="local">
          'Selection of agent'
         </a>
         above and
         <a class="local">
          'Renal failure'
         </a>
         above and
         <a class="local">
          'Hemodynamic instability'
         </a>
         above and
         <a class="local">
          'Extensive clot burden'
         </a>
         above and
         <a class="local">
          'Anticipated need for discontinuation or reversal'
         </a>
         above and
         <a class="local">
          'Obesity or poor subcutaneous absorption'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13611271">
         <span class="h3">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial dosing of subcutaneous and IV UFH is also weight based, but unaffected by renal insufficiency. We prefer weight-based protocols  (
         <a class="graphic graphic_table graphicRef122945" href="/z/d/graphic/122945.html" rel="external">
          table 6
         </a>
         ) rather than fixed-dose protocols  (
         <a class="graphic graphic_table graphicRef66081 graphicRef72792" href="/z/d/graphic/66081.html" rel="external">
          table 7A-B
         </a>
         ) because they make pharmacologic sense and improve time spent within the therapeutic range [
         <a href="#rid41">
          41-43
         </a>
         ]. Use of anticoagulation tests is described separately. (See
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests", section on 'Monitoring heparins'
         </a>
         .)
        </p>
        <p>
         The use of
         <strong>
          IV UFH protocols
         </strong>
         may increase the time spent in the therapeutic range. Achieving and maintaining a therapeutic aPTT range can be challenging [
         <a href="#rid44">
          44-47
         </a>
         ]. As an example, one observational study reported that 60 percent of treated patients failed to achieve an adequate aPTT response during the initial 24 hours of therapy and that 30 to 40 percent of patients remained subtherapeutic over the next three to four days [
         <a href="#rid45">
          45
         </a>
         ]. These observations led to protocols designed to efficiently achieve and maintain target aPTT goals. Commonly used protocols are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight-based  (
         <a class="graphic graphic_table graphicRef122945" href="/z/d/graphic/122945.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid42">
          42
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-weight based  (
         <a class="graphic graphic_table graphicRef66081 graphicRef72792" href="/z/d/graphic/66081.html" rel="external">
          table 7A-B
         </a>
         ) [
         <a href="#rid43">
          43
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The preference for weight-based protocols is primarily based upon a randomized trial of a mixed population of patients requiring IV UFH for several different indications (venous and arterial thrombosis, unstable angina). In that trial, a weight-based heparin dosing nomogram  (
         <a class="graphic graphic_table graphicRef66081 graphicRef72792" href="/z/d/graphic/66081.html" rel="external">
          table 7A-B
         </a>
         ) was compared with a non-weight-based nomogram to maintain a therapeutic aPTT ratio  (
         <a class="graphic graphic_table graphicRef122945" href="/z/d/graphic/122945.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid42">
          42
         </a>
         ]. Patients treated with the weight-adjusted regimen received a starting bolus dose of 80 units/kg followed by an 18 units/kg per hour infusion; subsequent adjustments were made every six hours. Patients in the standard-care group received a bolus of 5000 units followed by a 1000 units/hour infusion; subsequent fixed-dose adjustments were made every six hours. A higher percentage of patients in the weight-adjusted group achieved a therapeutic aPTT within 24 hours (97 versus 77 percent) without an increase in major bleeding. Recurrent thromboembolism was more frequent in the non-weight-based group (relative risk 5.0, 95% CI 1.1-21.9). This protocol is generalizable and widely used routinely in clinical practice. However, data still suggest that a large proportion of patients anticoagulated for PE, for example, remain outside of the therapeutic range during the first 48 hours (up to two-thirds) [
         <a href="#rid48">
          48
         </a>
         ]. Use of coagulation tests is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests", section on 'Monitoring heparins'
         </a>
         .)
        </p>
        <p>
         Although not routine, weight-adjusted
         <strong>
          subcutaneous UFH
         </strong>
         has been used for patients who decline IV access and have a contraindication to LMW heparin (eg, severe renal insufficiency) or other anticoagulants [
         <a href="#rid24">
          24
         </a>
         ]. Typically, subcutaneous UFH is given as a weight-based dosing of 333 units/kg loading dose followed by 250 units/kg every 12 hours [
         <a href="#rid9">
          9
         </a>
         ]. The dose is then titrated to achieve a therapeutic aPTT. The first aPTT is generally measured six hours after the second dose. Most adjustments should be an increase or decrease of 10 to 30 percent. The aPTT may be measured six hours after the second injection that follows each dose adjustment. Once a stable dose is achieved, the aPTT may be measured after three to four days of treatment and then every few weeks. In rare circumstances, a transition from IV UFH to subcutaneous UFH is needed. The transition is traditionally done after the patient has received IV UFH for 5 to 10 days and a loading dose of subcutaneous UFH is not needed [
         <a href="#rid49">
          49
         </a>
         ]. In this situation, the first aPTT can be checked six hours after the first subcutaneous UFH dose and then six hours after every dose adjustment until a stable dose that produces the desired therapeutic level is achieved.
        </p>
        <p class="bulletIndent1">
         Optimal dosing of UFH in patients with obesity is unknown. Most physicians use ideal body weight to guide dosing and increase the aPTT accordingly to the target. The clinical efficacy of this approach is unknown. (See
         <a class="medical medical_review" href="/z/d/html/584.html" rel="external">
          "Intensive care unit management of patients with obesity", section on 'Anticoagulants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Additional therapeutic uses of UFH are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Unfractionated heparin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13611277">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the past,
         <strong>
          IV UFH
         </strong>
         was the gold standard for initial anticoagulation in patients with DVT until LMW heparin became available. Compared with LMW heparin, use of IV UFH is associated with slightly higher rates of recurrent thrombosis and major bleeding. Comparative studies between LMW heparin and IV UFH are discussed in detail separately. (See
         <a class="local">
          'Selection of agent'
         </a>
         above and
         <a class="local">
          'Low molecular weight heparin'
         </a>
         above.)
        </p>
        <p>
         The efficacy of IV UFH depends upon achieving a critical therapeutic level as soon as possible, preferably within the first 24 hours of treatment, usually via a continuous IV infusion [
         <a href="#rid10">
          10,21,42,50-55
         </a>
         ]. Monitoring the therapeutic level of heparin is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Dosing and monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests", section on 'Monitoring heparins'
         </a>
         .)
        </p>
        <p>
         Studies that support this target range include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One older prospective study of patients with acute DVT reported that, compared with an aPTT ratio &gt;1.5, patients who had an aPTT ratio &lt;1.5 times the control for three days had a threefold increase in the risk of recurrent thrombosis [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis of three randomized trials examined therapeutic or subtherapeutic UFH (mostly IV UFH) for acute proximal DVT [
         <a href="#rid54">
          54
         </a>
         ]. Compared with patients whose aPTT exceeded the therapeutic threshold by 24 hours, failure to achieve a therapeutic aPTT during that time was associated with an increased rate of recurrent thrombosis (23 percent versus 4 percent).
        </p>
        <p>
        </p>
        <p>
         Although there is a strong correlation between subtherapeutic aPTT values and recurrent thromboembolism, the relationship between supratherapeutic aPTT (ie, an aPTT ratio 2.5 or more) and bleeding is less definite [
         <a href="#rid43">
          43
         </a>
         ]. Nonetheless, aiming for a therapeutic range with the avoidance of periods of both subtherapeutic and supratherapeutic levels is prudent.
        </p>
        <p>
         The advantages of IV UFH compared with LMW heparin include its lower cost and its safe use in those with renal insufficiency. An additional advantage of the IV formulation is its short half-life, particularly for patients in whom there is a potential need for acute discontinuation (eg, surgery). Disadvantages are that infusions of UFH require hospital admission, and both subcutaneous and IV UFH are associated with a higher potential for HIT. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Other complications'
         </a>
         .)
        </p>
        <p>
         Data that support efficacy of subcutaneous UFH include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One meta-analysis of 16 randomized trials of patients with VTE, when compared with continuous IV UFH for initial anticoagulation, subcutaneous UFH resulted in similar rates of recurrence (5.7 versus 3.5 percent), mortality (0.3 percent each), and major bleeding (4.4 versus 4.8 percent) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another meta-analyses [
         <a href="#rid8">
          8
         </a>
         ] of four randomized trials [
         <a href="#rid21">
          21,23,24,56
         </a>
         ] demonstrated that LMW heparin and subcutaneous UFH have similar effects on mortality (4.3 versus 4 percent with subcutaneous UFH), recurrent thromboembolic events (3.3 versus 4 percent with subcutaneous UFH), and major bleeding (2.3 versus 1.8 percent with subcutaneous UFH).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H796357767">
         <span class="h2">
          Direct factor Xa and thrombin inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral factor Xa (
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         ) or direct thrombin inhibitors (
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         ) are attractive candidates as initial oral anticoagulants in patients with acute VTE due to their quick onset of action (peak efficacy one to four hours after ingestion). Rivaroxaban and apixaban were evaluated as anticoagulants without prior administration of heparin (ie, monotherapy); as such they may be used as the sole initial anticoagulant. However, anticoagulant therapy with heparin should not be delayed while the decision is being made to treat with one of these agents and assurance needs to be obtained that the drug is available immediately (as an inpatient or outpatient). In contrast, in trials that evaluated dabigatran and edoxaban, all patients were treated with five days of heparin prior to their administration (ie, sequential therapy); as such, we prefer that a short course of heparin (typically LMW heparin) be administered alone before transitioning to either dabigatran or edoxaban. (See
         <a class="local">
          'Selection of agent'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H105734355">
         <span class="h3">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typical
         <strong>
          initial
         </strong>
         doses in those with normal renal function are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          Rivaroxaban
         </a>
         15 mg twice daily (for the first three weeks)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          Apixaban
         </a>
         10 mg twice daily (for first seven days)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          Edoxaban
         </a>
         60 mg once daily (and 30 mg once daily in patients with a body weight below 60 kg) (after an initial 5 to 10 days of parenteral anticoagulation)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          Dabigatran
         </a>
         150 mg twice daily (after an initial 5 to 10 days of parenteral anticoagulation)
        </p>
        <p>
        </p>
        <p>
         In keeping with the clinical trials that demonstrated their efficacy, in patients who are receiving heparin as the initial anticoagulant, we prefer that oral factor Xa or direct thrombin inhibitors be given within 6 to 12 hours following the last dose of subcutaneous LMW heparin when administered as a twice daily regimen, or within 12 to 24 hours for once daily regimens. Infusions of UFH can be immediately discontinued following the administration of these oral agents. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Agents for long-term anticoagulation'
         </a>
         .)
        </p>
        <p>
         Many of these agents are renally excreted such that patients with severe renal insufficiency should
         <strong>
          not
         </strong>
         be considered for these agents. The distribution of agent and anticoagulant effect in the obese population is unknown. Maintenance doses for long-term anticoagulation and further details regarding dosing in renal insufficiency are discussed in the UpToDate
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         and in additional topics. (See
         <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">
          "Management of bleeding in patients receiving direct oral anticoagulants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Direct thrombin and factor Xa inhibitors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Chronic kidney disease'
         </a>
         .)
        </p>
        <p>
         The efficacy and safety of factor Xa and direct thrombin inhibitors as anticoagulants for extensive DVT (eg, patients with phlegmasia cerulea dolens) or hemodynamically significant pulmonary embolism are unknown, and, as such, they should
         <strong>
          not
         </strong>
         be used in these patients who may receive thrombolytic therapy. Similarly, we prefer that these agents
         <strong>
          not
         </strong>
         be administered in patients who are pregnant, because their safety and efficacy is unproven in this population. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Phlegmasia cerulea dolens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1350.html" rel="external">
          "Venous thromboembolism in pregnancy and postpartum: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H105734349">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized trials of these oral agents in patients with acute VTE examined efficacy and safety in the context of long-term anticoagulation with the same oral agent for three months or more. When compared with conventional courses of LMW heparin or IV UFH followed by long-term anticoagulation with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , these agents had similar rates of recurrent thrombosis and major hemorrhage [
         <a href="#rid57">
          57-60
         </a>
         ]. However, trials that reported efficacy for
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         (direct thrombin inhibitor) and
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         (factor Xa inhibitor) used a minimum of five days of anticoagulation with LMW heparin or UFH prior to their administration for long-term oral therapy (ie, sequential therapy) [
         <a href="#rid59">
          59,60
         </a>
         ]. In contrast, trials of
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         and
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         reported efficacy of both agents as the sole initial anticoagulant (monotherapy). Although short periods (&lt;48 hours) of heparin were allowed prior to randomization, our experience with these agents is in keeping with the data that suggest monotherapy with these agents is safe and effective. Details of the trials that reported the safety and efficacy of these agents for the long-term treatment of VTE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Direct thrombin and factor Xa inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13608174">
         <span class="h1">
          DURATION OF THERAPY FOR HEPARIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial duration of heparin therapy varies depending upon the oral agent chosen and whether or not thrombolysis is anticipated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Factor Xa and direct thrombin inhibitors
         </strong>
         – When factor Xa and direct thrombin inhibitors are chosen, co-administration with heparin is not warranted. However, short courses of heparin are acceptable in those on
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         and
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         , while typically five days is required for those on
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         and
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         . (See
         <a class="local">
          'Direct factor Xa and thrombin inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         – When administered together with warfarin on day 1, there is no benefit to prolonged courses of systemic heparin beyond a therapeutic INR  (
         <a class="graphic graphic_table graphicRef71791" href="/z/d/graphic/71791.html" rel="external">
          table 8
         </a>
         ). Randomized trials have reported that shorter courses of heparin therapy (typically four to five days) plus initiation of warfarin on day 1 is as effective as longer courses of heparin (10 to 14 days) with the delayed initiation of warfarin (eg, starting day 5 to 10) [
         <a href="#rid41">
          41,56,61
         </a>
         ]. As an example, in one randomized trial of patients treated with parenteral heparin for proximal DVT, the initiation of warfarin on day 1 of therapy was associated with an equivalent three-month rate of recurrent VTE when compared with warfarin started on day 5 to 10 of therapy (7 percent each) [
         <a href="#rid61">
          61
         </a>
         ]. This approach has the added advantage of minimizing the total number of days that a patient requires anticoagulation with heparin, thereby reducing the risk of HIT [
         <a href="#rid36">
          36
         </a>
         ]. In clinical practice, the same approach is acceptable for patients taking subcutaneous LMW heparin, UFH, and
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anticipated thrombolysis
         </strong>
         – Since a small proportion of patients with heavy clot burden in the lower extremity or submassive pulmonary embolus (PE) may need thrombolysis, IV UFH is usually administered for an ill-define period (sometimes up to 48 hours) until it is assessed by the clinician that thrombolysis is not indicated. There are no guidelines to facilitate the duration of heparin under these circumstances. (See
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Details of transitioning to long-term maintenance therapy are discussed separately. (See
         <a class="local">
          'Transitioning to maintenance therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8155842">
         <span class="h1">
          EMPIRIC ANTICOAGULATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to empirically anticoagulate while waiting for diagnostic test results depends upon the clinical suspicion for VTE  (
         <a class="graphic graphic_table graphicRef75871" href="/z/d/graphic/75871.html" rel="external">
          table 9
         </a>
         ), the expected timing of diagnostic tests, and the bleeding risk. Our strategy is similar for patients with deep vein thrombosis (DVT) and/or pulmonary embolism and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Empiric anticoagulation'
         </a>
         .)
        </p>
        <p>
         The diagnosis of DVT is also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">
          "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H796359443">
         <span class="h1">
          TRANSITIONING TO MAINTENANCE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic anticoagulation should be ensured during the transition from initial to long-term (maintenance) therapy  (
         <a class="graphic graphic_table graphicRef120639" href="/z/d/graphic/120639.html" rel="external">
          table 10
         </a>
         ). The optimal transition strategy varies with the long-term anticoagulant chosen and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Agents for long-term anticoagulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Transitioning between anticoagulants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2237118247">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">
          "Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">
          "Society guideline links: Anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8155879">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (See
         <a class="medical medical_patient" href="/z/d/html/693.html" rel="external">
          "Patient education: Deep vein thrombosis (DVT) (Beyond the Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/693.html" rel="external">
          "Patient education: Deep vein thrombosis (DVT) (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/689.html" rel="external">
          "Patient education: Warfarin (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8155885">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nomenclature
         </strong>
         – Initial anticoagulation refers to anticoagulant therapy that is administered immediately following diagnosis of acute venous thromboembolism (VTE); it is often given over the first few days (typically from 0 to 10 days) while planning for long-term anticoagulation. Anticoagulation should be started immediately as a delay increases the risk of embolization and death. (See
         <a class="local">
          'Nomenclature'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bleeding risk
         </strong>
         – Every patient with acute VTE should be assessed for the risk of bleeding prior to anticoagulation. Most clinicians agree that anticoagulation should be administered to patients with a low risk of bleeding and avoided in those at high risk  (
         <a class="graphic graphic_table graphicRef97160" href="/z/d/graphic/97160.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef107543" href="/z/d/graphic/107543.html" rel="external">
          table 2
         </a>
         ). For patients with a moderate risk of bleeding, the decision to anticoagulate must be individualized according to the values and preferences of the patient as well as the risk-benefit ratio as assessed by the clinician. (See
         <a class="local">
          'Bleeding risk'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Assessing bleeding risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">
          "Risks and prevention of bleeding with oral anticoagulants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'Assessing the risk of bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-line anticoagulant
         </strong>
         – For most patients with acute VTE, we suggest subcutaneous low molecular weight (LMW) heparin, subcutaneous
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         , or the oral factor Xa inhibitors,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         or
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         , rather than intravenous (IV)
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A decision between these agents is usually made based upon clinician experience as well as the risks of bleeding, patient comorbidities, preferences, cost, and convenience  (
         <a class="graphic graphic_table graphicRef107541" href="/z/d/graphic/107541.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">
          table 5
         </a>
         ). Dosing for each agent is individualized. (See
         <a class="local">
          'Selection of agent'
         </a>
         above and
         <a class="local">
          'Low molecular weight heparin'
         </a>
         above and
         <a class="local">
          'Fondaparinux'
         </a>
         above and
         <a class="local">
          'Direct factor Xa and thrombin inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special populations
         </strong>
         – Other populations require special consideration:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Renal failure or poor absorption
         </strong>
         – For most patients with acute VTE who have severe renal failure (eg, creatinine clearance &lt;30 mL/minute), hemodynamic instability, or massive iliofemoral deep vein thrombosis, or for patients in whom there is a high likelihood of needing to acutely discontinue or reverse anticoagulation, we suggest IV UFH rather than LMW heparin (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). IV UFH may also be an alternative to LMW heparin when subcutaneous absorption is potentially poor (eg, massive edema, anasarca). A weight-based protocol is preferably used to administer UFH at a dose sufficient to prolong the activated partial thromboplastin time (aPTT), with a target aPTT ratio of 1.5 to 2.5 over the control  (
         <a class="graphic graphic_table graphicRef122945" href="/z/d/graphic/122945.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Selection of agent'
         </a>
         above and
         <a class="local">
          'Unfractionated heparin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Others
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For pregnant females, LMW heparin is the preferred initial anticoagulant. (See
         <a class="medical medical_review" href="/z/d/html/1350.html" rel="external">
          "Venous thromboembolism in pregnancy and postpartum: Treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with malignancy, first-line agents include LMW heparin and select direct oral anticoagulants. (See
         <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">
          "Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with heparin-induced thrombocytopenia, heparin is contraindicated, and immediate anticoagulation with a non-heparin anticoagulant (eg,
         <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">
          argatroban
         </a>
         ,
         <a class="drug drug_general" data-topicid="9320" href="/z/d/drug information/9320.html" rel="external">
          danaparoid
         </a>
         ,
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         ,
         <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">
          bivalirudin
         </a>
         ) is indicated. (See
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outpatient therapy
         </strong>
         – Outpatient rather than inpatient anticoagulation can be considered in select patients  (
         <a class="graphic graphic_table graphicRef70140" href="/z/d/graphic/70140.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Outpatient versus inpatient therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Outpatient anticoagulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Empiric anticoagulation
         </strong>
         – The decision to empirically anticoagulate while waiting for diagnostic test results depends upon the clinical suspicion for VTE  (
         <a class="graphic graphic_table graphicRef75871" href="/z/d/graphic/75871.html" rel="external">
          table 9
         </a>
         ), the expected timing of diagnostic tests, and the bleeding risk. (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Empiric anticoagulation'
         </a>
         and
         <a class="local">
          'Empiric anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transitioning to maintenance
         </strong>
         – Full anticoagulation should be ensured during the transition from initial to long-term (maintenance) therapy when switching agents. (See
         <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">
          "Venous thromboembolism: Anticoagulation after initial management", section on 'Agents for long-term anticoagulation'
         </a>
         and
         <a class="local">
          'Transitioning to maintenance therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Transitioning between anticoagulants'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Raja AS, Greenberg JO, Qaseem A, et al. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2015; 163:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4:4693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160:e545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husted S, de Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Exter PL, van Es J, Erkens PM, et al. Impact of delay in clinical presentation on the diagnostic management and prognosis of patients with suspected pulmonary embolism. Am J Respir Crit Care Med 2013; 187:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SB, Geske JB, Maguire JM, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 2010; 137:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hacobian M, Shetty R, Niles CM, et al. Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study. Clin Appl Thromb Hemost 2010; 16:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong BH, Brighton TA, Baker RI, et al. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis 2005; 19:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007; 146:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakkar VV, Hoppenstead DA, Fareed J, et al. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002; 99:1965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breddin HK, Hach-Wunderle V, Nakov R, et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prandoni P, Carnovali M, Marchiori A, Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faivre R, Neuhart Y, Kieffer Y, et al. [A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study]. Presse Med 1988; 17:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castellucci LA, Cameron C, Le Gal G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 2014; 312:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2017; 2:CD001100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005; 165:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost 2001; 86:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhutia S, Wong PF. Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2013; :CD003074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dongen CJ, MacGillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2005; :CD003074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charbonnier BA, Fiessinger JN, Banga JD, et al. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group. Thromb Haemost 1998; 79:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmoström M, Berglund MC, Granquist S, et al. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res 1992; 67:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegbahn A, Y-Hassan S, Boberg J, et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res 1989; 55:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trujillo-Santos J, Bergmann JF, Bortoluzzi C, et al. Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. J Thromb Haemost 2017; 15:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e495S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandao GM, Junqueira DR, Rollo HA, Sobreira ML. Pentasaccharides for the treatment of deep vein thrombosis. Cochrane Database Syst Rev 2017; 12:CD011782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leroyer C, Bressollette L, Oger E, et al. Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study Group. Haemostasis 1998; 28:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fennerty AG, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. Br Med J (Clin Res Ed) 1985; 290:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 1988; 148:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hylek EM, Regan S, Henault LE, et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 2003; 163:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prucnal CK, Jansson PS, Deadmon E, et al. Analysis of Partial Thromboplastin Times in Patients With Pulmonary Embolism During the First 48 Hours of Anticoagulation With Unfractionated Heparin. Acad Emerg Med 2020; 27:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandjes DP, Heijboer H, Büller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327:1485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med 1997; 157:2317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157:2562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:188S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369:1406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322:1260.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 95336 Version 55.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26414967" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33007077" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31473594" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34352278" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24658395" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23590273" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Impact of delay in clinical presentation on the diagnostic management and prognosis of patients with suspected pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20081101" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315268" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315259" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315264" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19147527" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16082604" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17261856" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Management of venous thromboembolism: a systematic review for a practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11877267" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7887755" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8629671" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10647756" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11177331" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11228276" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10366369" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15159264" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2965375" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : [A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1325076" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16926353" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25226478" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14757615" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28182249" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15824291" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11686355" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23857562" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16034885" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Once versus twice daily LMWH for the initial treatment of venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9609216" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1332213" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2551070" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28120516" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315270" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278467" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Low-molecular-weight heparins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15172900" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29199766" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pentasaccharides for the treatment of deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14585937" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10087431" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8214998" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1497392" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Optimal therapeutic level of heparin therapy in patients with venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3917323" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Audit of control of heparin treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3377615" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Physician practices in the treatment of pulmonary embolism and deep venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1789820" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A standard heparin nomogram for the management of heparin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12622610" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31625654" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Analysis of Partial Thromboplastin Times in Patients With Pulmonary Embolism During the First 48 Hours of Anticoagulation With Unfractionated Heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8649471" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Venous thromboembolism during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5041701" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3531862" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1406880" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9361572" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9531224" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15383472" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2878173" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21128814" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Oral rivaroxaban for symptomatic venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23808982" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Oral apixaban for the treatment of acute venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23991658" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19966341" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2183055" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
